GZMB and neoplasm: Interestingly, our ex-vivo studies showed that S100A8 is a potent activator of NK cells, as indicated by increased expression of granzyme B (82), thus it is plausible that treating tumor-bearing mice with S100A8 may induce activation and function of NK cells without altering their numbers.